Detailed Narrative
Oncology Milestones and Regulatory Successes
Natera achieved several crucial oncology milestones for Signatera, including its U.S. FDA approval as a companion diagnostic for muscle-invasive bladder cancer, making it the first MRD test to receive such approval. It also secured Japanese PMDA approval for colorectal cancer and IVDR certification in the EU for over 20 tumor types, streamlining future clinical trials and setting up for future reimbursement in Europe. The NCCN Guideline Committee issued a Category 1 recommendation for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer, expected to drive adoption and positive commercial payer coverage policies.
Women's Health Product Innovation
The company launched its enhanced Panorama test, powered by novel SNP-informed deep sequencing technology, which significantly reduces the no-call rate to 0.5% (an 80% improvement) and demonstrates 100% detection of trisomy 21 in low fetal fraction patients. This enhancement, along with the successful Fetal Focus (single-gene NIPT) and Fetal RhD tests, has led to strong new account wins and positions Natera competitively in women's health.
Organ Health Medicare Coverage Expansion
The final Medicare LCD for organ transplant surveillance was published in July, representing a meaningful expansion of coverage for Prospera. Medicare will now cover 6 tests for kidney transplant patients and 12 tests for heart and lung transplant patients in year 1 post-surgery, and 4 tests per year across all three categories in years 2 and 3. This policy, effective August 30, is expected to drive improvements in Prospera ASP and volumes.
Clinical Evidence Engine and SIGNAL Program
Natera has built a robust clinical evidence engine for Signatera, initiating over 70 prospective studies since 2019. These studies are now beginning to read out, with the pace expected to accelerate, providing catalysts for guidelines, reimbursement, and volume. The company introduced SIGNAL-ER 101, its first Natera-sponsored interventional prospective study in HR+/HER2- breast cancer, aiming to use Signatera to identify patients who truly need CDK4/6 inhibitors, potentially changing practice and reducing overtreatment.
Early Cancer Detection (ECD) Progress
The pivotal FIND study for early cancer detection is approaching full enrollment, with approximately 24,000 average risk adults enrolled to date and completion expected in Q3 FY26. The company plans to read out the FIND cohort in 2027, with ongoing productive conversations with the FDA. Natera remains enthusiastic about developing a differentiated product with high sensitivity for advanced adenomas.